# BeBetter Med

Source: https://onco.cc/companies/bebetter-med/  
OnCo record `bebetter-med` (Company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

BeBetter Med is a Guangzhou biotechnology company developing BEBT-908, a dual PI3K and HDAC inhibitor for relapsed lymphoma, and other small-molecule cancer drugs, with three late-stage trials in the registry.

## Summary

BeBetter Med, based in Guangzhou, develops small-molecule cancer drugs. Its lead programme BEBT-908 inhibits both PI3K and histone deacetylases and has been studied in relapsed or refractory diffuse large B-cell lymphoma and other lymphomas, and the company runs further trials of its pipeline in solid tumours. Sponsor and trial facts are from the ClinicalTrials.gov registry; company facts are from the official website.

## Fields

- Kind: Company
- Last checked: 2026-09-11
- Also known as: BeBetter Medicine; Guangzhou BeBetter Medicine Technology
- Tags: ctgov-sponsor
- HQ: Guangzhou
- Type: biotech
- Website: https://www.bebettermed.com/

## Sources

- Official website: https://www.bebettermed.com/
- ClinicalTrials.gov: trials led by BeBetter Med: https://clinicaltrials.gov/search?lead=BeBetter%20Med

## Connected records

- cancers: [Diffuse large B-cell lymphoma](https://onco.cc/cancers/dlbcl/)
- fronts: [Targeted Therapy](https://onco.cc/fronts/targeted-therapy/)
- drugs: [BEBT-209](https://onco.cc/drugs/bebt-209/), [Ifupinostat](https://onco.cc/drugs/ifupinostat/)
- trials: [A Study of BEBT-209 Plus Chemotherapy in Patients With Locally Advanced or Metastatic Triple-Negative Breast Cancer](https://onco.cc/trials/nct07544056/), [Study Comparing BEBT-908 Combined With R to SOC for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma](https://onco.cc/trials/nct06792253/), [Study of BEBT-109 in Subjects With EGFR Exon 20 Insertion Mutations Non-Small Cell Lung Cancer](https://onco.cc/trials/nct06706713/), [Study of BEBT-109 in Subjects With Non-Small Cell Lung Cancer Carrying EGFR Exon 20 Insertion Mutations](https://onco.cc/trials/nct06514027/), [Study of BEBT-209 in Combination With Fulvestrant Versus Placebo in Combination With Fulvestrant in Patients With HR+/HER2- Locally Advanced or Metastatic Breast Cancer Who Have Progressed After Prior Endocrine Therapy](https://onco.cc/trials/nct06998108/)

---
JSON: https://onco.cc/api/v1/entities/bebetter-med.json